---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030297"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:11:17.293398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma signs exclusive agreement with Lupin to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada

## Summary
- Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.
- Adzenys XR-ODT and Cotempla XR-ODT are the only extended-release orally disintegrating ADHD tablets; Health Canada approval needed.
- Aytu's ADHD prescriptions grew 16.5% over two years; Canadian stimulant market was $1.1B CAD (4.5M units) in 2023.
- Lupin will seek regulatory approvals over 18-24 months; financial terms not disclosed.

## SEC filing metadata
- accession: 0001437749-24-030297
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/0001437749-24-030297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/aytu20240723_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030297
- JSON: https://secwatch.observer/filing/0001437749-24-030297.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.